Genetic biomarker for cancer immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit.Cancer cell · 2025
   Review
2. Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.ESMO open · 2024
   Observational
3. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.Biomedicines · 2022
   Review
4. TraPS-VarI: Identifying genetic variants altering phosphotyrosine based signalling motifs.Scientific reports · 2020
   Article
5. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells.eLife · 2019
   Article
6. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.Oncoimmunology
   Review

Corrections and comments

• Comment on
  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as